Persistently elevated expression of systemic, soluble co-inhibitory immune checkpoint molecules in people living with HIV before and one year after antiretroviral therapy

Loading...
Thumbnail Image

Authors

Labuschagne Naidoo, Robyn-Brooke
Theron, Annette J.
Anderson, Ronald
Tintinger, Gregory Ronald
Rossouw, Theresa M.

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI

Abstract

Please read abstract in article.

Description

DATA AVAILABILITY STATEMENT: The data that support the findings of this study are available from the corresponding author upon reasonable request.
SUPPORTING INFORMATION: TABLE S1: Comparison of soluble immune checkpoint levels between female and male PLWH before ART; TABLE S2: Comparison of soluble immune checkpoint levels between female and male PLWH after 12 months of ART; TABLE S3: Comparison of the change in soluble immune checkpoint levels before and after 12 months of ART between tobacco-users and non-users; TABLE S4: Correlations between age and soluble immune checkpoint molecules before treatment in PLWH.

Keywords

Antiretroviral treatment, Co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1, PD-L1, TIM-3, SDG-03: Good health and well-being, SDG-09: Industry, innovation and infrastructure, Antiretroviral therapy (ART), Human immunodeficiency virus (HIV)

Sustainable Development Goals

SDG-03:Good heatlh and well-being
SDG-09: Industry, innovation and infrastructure

Citation

Labuschagne Naidoo, R.-B.; Steel, H.C.; Theron, A.J.; Anderson, R.; Tintinger, G.R.; Rossouw, T.M. Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy. Pathogens 2024, 13, 540. https://doi.org/10.3390/pathogens13070540.